Crinetics reveals positive topline primary and secondary endpoint data in PhIII acromegaly trial
Crinetics’ first of two Phase III trials investigating its drug paltusotine in acromegaly read out positive topline data Sunday, with the drug hitting the primary endpoint and all secondary endpoints, bolstering the company’s plans to file for an NDA next year.
Paltusotine, an oral, once-daily selectively targeted somatostatin receptor type 2 agonist, earned a p-value of p<0.0001 on the primary endpoint investigating the proportion of participants taking paltusotine who maintained an insulin-like growth factor 1 (IGF-1) level less than or equal to 1.0 times the upper limit of normal. In the PATHFNDR-1 study, 83% of patients on Crinetics’ drug maintained the IGF-1 levels compared to just 4% on placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.